Asia breast cancer screening market is expected to reach US$ 275.6 million by 2028
Renub Research has recently published a report named "Asia Breast Cancer Screening Market: Global Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2022-2028," providing a detailed industry analysis that consists of market share insights. Furthermore, the report encompasses a study of competitors and regions and the recent growth in the Asia Breast Cancer Screening Market.
Expert Insights: Ask Analyst or Download Full Report with TOC & Figures: https://www.renub.com/asia-breast-cancer-screening-market-forecast-mammography-mri-and-ultrasound-1122-p.php
Asia breast cancer screening market is expected to grow significantly between 2022 and 2028, at a CAGR of 4.14%.Breast cancer (BC) is the most frequently diagnosed malignancy and the leading cause of death for women. The number of new cases and deaths worldwide was estimated to be 2.3 million and 684,996, respectively. Breast Cancer, a major women’s health difficulty, has been gaining interest as its prevalence and mortality are growing, making it the 5th main motive of most cancers mortality. Nearly 1/2 of the breast most cancers patients were recognized in Asia.
Asian ladies are recognized with most breast cancers at a youth age than their Western women. The peak age for breast cancer occurrence in Asian locations is generally among 40 and 50 years, whereas it's miles generally among 60 and 70 years in Western countries. This disparity emphasizes the significance of taking local and demographic factors into consideration while developing breast cancers prevention, screening, and remedy techniques. Understanding these variations can assist tailor healthcare strategies to successfully cope with the unique needs and demanding situations faced with the aid of exceptional populations in the fight against breast most cancers.
Breast cancer consciousness is growing in Asia, way to public training campaigns, government tasks, and expanded screening offerings. Screening offerings are becoming extra reachable because of authorities investments, the enlargement of private healthcare providers, and the usage of telemedicine. Furthermore, the place is seeing an increase in demand for early breast most cancers detection, which could cause extra powerful treatment and a better analysis.
Increasing research activities are likely to boost the Asia-Pacific breast cancer screening market. In Japan, for example, a study called "Novel combination of serum microRNA for detecting breast cancer in the early stage" was carried out. Furthermore, because cancer is one of the leading causes of death in Japan, the Japanese government has initiated cancer control programs. Municipalities throughout the country run cancer screening programs with government funding.
Increasing research activities are in all likelihood to boost the Asia-Pacific breast cancer screening market. In Japan, for instance, a study called "Novel aggregate of serum microRNA for detecting breast cancers in the early level"was carried out. Furthermore, due to one of the main causes of demise in Japan, the Japanese government has initiated cancer manage packages. Municipalities throughout the country run most cancers screening programs with authority’s investment.
China is poised to make widespread advancements in Asia's breast most cancers screening market.
Healthcare professionals and the general public are becoming more aware of breast cancer because of its rising prevalence, fuelled by aging populations and lifestyle changes. The need for early detection greatly enhances treatment outcomes as more screening services become available.A large and well-functioning healthcare system, a steadfast government commitment to public health, and a developing technological infrastructure are just a few of China's advantages. These factors make it possible to create and implement cutting-edge screening and prevention programs. China is in a strong position to significantly impact breast cancer prevention and treatment thanks to its resources and resolve.
Request a free sample copy of the report: https://www.renub.com/request-sample-page.php?gturl=asia-breast-cancer-screening-market-forecast-mammography-mri-and-ultrasound-1122-p.php
Asia Breast Cancer Screening Market- Breast cancer screening markets have been examined in seven Asian countries.
1. China
2. India
3. Japan
4. Korea
5. Singapore
6. Thailand
7. Malaysia
India is surfacing as the augmenting market in the Asia Breast Cancer Mammography screening industry.
India has a high prevalence of breast cancer, and the incidence is rising due to aging populations, altered lifestyles, and genetics. About 1,62,468 new cases and 87,090 fatalities are anticipated in 2022, making it responsible for 25% of all cancers in women. According to GLOBOCON predictions, breast cancer cases will increase by 70% between 2020 and 2040.Public education campaigns, government initiatives, and improved screening services' availability, including telemedicine, are driving the country's growing awareness of breast cancer. For better treatment outcomes, early detection is desired. Government policies that are helpful, such as funding for screening initiatives and tax exemptions on screening tools, help India's healthcare system deal with this problem.
Mammography Screening - The Asia breast cancer screening markets in seven countries.
1. China
2. India
3. Japan
4. Korea
5. Singapore
6. Thailand
7. Malaysia
The share of China in the Asia Breast Cancer MRI Screening market is anticipated to rise significantly.
China's substantial investment in healthcare, particularly in advanced medical technologies like MRI machines for breast cancer screening, coupled with efforts to expand healthcare coverage, raise awareness, and benefit from rapid advancements in medical technology, supported by strong government backing and increased healthcare expenditure, are all factors contributing to the expected substantial growth of China's market share in the Asian Breast Cancer MRI Screening sector.
MRI Screening - Research has been done on the Asia breast cancer screening markets in seven nations.
1. China
2. India
3. Japan
4. Korea
5. Singapore
6. Thailand
7. Malaysia
China will likely dominate the Asia market for breast cancer ultrasound screening.
The country's healthcare industry has recently seen impressive advancements in ultrasound technology, improving the accuracy and effectiveness of breast cancer diagnosis. The demand for ultrasound screening services has increased dramatically across China as people become more aware of the critical importance of early detection and screening.The government's programs to improve healthcare access, especially in rural areas, have significantly contributed to the sector's explosive growth. Collaborations between experts in the medical field, academic institutions, and powerful corporations have also been essential for fostering innovation and advancing the adoption of sophisticated ultrasound screening technologies.
Ultrasound Screening - A study of the Asia breast cancer screening markets in seven countries has been conducted.
1. China
2. India
3. Japan
4. Korea
5. Singapore
6. Thailand
7. Malaysia
Competitive Landscape.
Asia Breast Cancer Screening market consists of companies like AstraZeneca, Hologic Corporation, Becton, Siemens AG, Roche Diagnostics, Quest Diagnostics, and Cardinal Health.
Company Insights:
• Overview
• Recent Development
• Sales Analysis
Companies Covered in the Report:
1. AstraZeneca
2. Hologic Corporation
3. Becton
4. Siemens AG
5. Roche Diagnostics
6. Quest Diagnostics
7. Cardinal Health
Related Reports
Breast Cancer Screening Market, Size, Global Forecast 2023-2028
Asia Cervical Cancer Screening Market, Size, Forecast 2023-2028
Europe Breast Cancer Screening Market, Size, Forecast 2023-2028
About the Company:
Renub Research is a Market Research and Information Analysis company with more than 14 years of experience in Research, Survey, and Consulting. Our research helps companies to take business decisions: on strategy, organization, operations, technology, mergers & acquisitions, etc. Till now we have published more than 7000 syndicated reports and worked on more than 500 custom research projects. Currently, we are supplying data to EMIS, Bloomberg, Thomson Reuters, etc. We support many blue-chip companies by providing them with findings and perspectives across a wide range of markets.
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian